Assessment of Radiolabelled Derivatives of R954 for Detection of Bradykinin B1 Receptor in Cancer Cells: Studies on Glioblastoma Xenografts in Mice.

Miho Shukuri, Satoru Onoe, Tsubasa Karube, Risa Mokudai, Hayate Wakui, Haruka Asano, Shin Murai, Hiromichi Akizawa

Abstract read

In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

Theranostic Potential of a NewPharmaceutics · 2025
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Miho ShukuriLaboratory of Physical Chemistry, Showa Pharmaceutical University, Tokyo 194-8543, Japan.

Satoru OnoeLaboratory of Physical Chemistry, Showa Pharmaceutical University, Tokyo 194-8543, Japan.ORCID 0000-0003-2143-314X

Tsubasa KarubeLaboratory of Physical Chemistry, Showa Pharmaceutical University, Tokyo 194-8543, Japan.

Risa MokudaiLaboratory of Physical Chemistry, Showa Pharmaceutical University, Tokyo 194-8543, Japan.

Hayate WakuiLaboratory of Physical Chemistry, Showa Pharmaceutical University, Tokyo 194-8543, Japan.

Haruka AsanoLaboratory of Physical Chemistry, Showa Pharmaceutical University, Tokyo 194-8543, Japan.

Shin MuraiLaboratory of Physical Chemistry, Showa Pharmaceutical University, Tokyo 194-8543, Japan.

Hiromichi AkizawaLaboratory of Physical Chemistry, Showa Pharmaceutical University, Tokyo 194-8543, Japan.ORCID 0000-0002-4787-785X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bradykinin B1 receptor (B1R) has garnered attention as a cancer therapeutic and diagnostic target. Several reports on radiolabelled derivatives of B1R antagonists have shown favourable properties as imaging agents in cells highly expressing hB1R following transfection. In the present study, we assessed whether radiolabelled probes can detect B1R endogenously expressed in cancer cells. To this end, we evaluated

Indexed as

bradykinin B1 receptorglioblastomamolecular imagingnuclear imagingR954

Identifiers

PMID39065752

DOI10.3390/ph17070902

PMCPMC11279923

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.